Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03927820 · ClinicalTrials.gov registry record · NA

A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)

A NA study of Asthma and COPD, sponsored by Vanderbilt University Medical Center.

Active
Registry status
NA
Development phase
914
Enrollment target
1
Study location

NCT03927820 is a NA study of Asthma and COPD that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 914 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03927820, a NA study of Asthma and COPD, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
914 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.

Conditions Studied

Interventions

  • OTHER Benefits investigation

Study Locations (1)

Tennessee

  • Vanderbilt Univeristy Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 914 participants
Start Date 2019-09-09
Est. Completion 2026-06
Phase NA

What the Registry Record Tells You About NCT03927820

The ClinicalTrials.gov registry entry for NCT03927820 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 914 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (41% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Benefits investigation is the first listed.

NCT03927820 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT03927820 about?

NCT03927820 is a clinical study titled "A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)". The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.

What is the current status of trial NCT03927820?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 914 participants. The study started on 2019-09-09. Estimated completion is 2026-06.

What conditions does trial NCT03927820 study?

This clinical trial studies the following conditions: Asthma, COPD.

What interventions are being tested in trial NCT03927820?

The interventions under investigation include: Benefits investigation (OTHER).

Who is sponsoring clinical trial NCT03927820?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03927820 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.